Document is current
Any future updates will be listed below
-
Authors
Fitzgerald, Kelly N. https://orcid.org/0000-0002-7521-0825
Motzer, Robert J. https://orcid.org/0000-0001-6925-2327
Lee, Chung-Han https://orcid.org/0000-0001-5511-0635
- License Information
-
More Information
Article History
Accepted: 30 September 2022
First Online: 11 November 2022
Competing interests
: R.J.M. reports grants from Bristol Myers Squibb, grants and personal fees from Pfizer, Novartis, Eisai, Exelixis, Merck and Genentech/Roche, and personal fees from Lilly, Incyte, EMD Serono Research and Development Institute, AVEO Pharmaceuticals and Takeda. C.-H.L reports honoraria from Intellisphere, Research to Practice and AiCME, consulting or advisory role with Amgen, Bristol Myers Squibb, Eisai, Exelixis, Merck and Pfizer/EMD Serono, institutional research funding from Bristol Myers Squibb, Calithera Biosciences, Eisai, Exelixis, Lilly, Merck and Pfizer, and travel/accommodation expenses from Calithera Biosciences and Eisai. K.N.F. declares no competing interests.
